Debt-to-equity of Oric Pharmaceuticals, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Oric Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Oric Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 8.5%, a 8.4% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Oric Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 8.5% -0.78% -8.4% 30 Sep 2025
Q2 2025 9.9% +0.52% +5.5% 30 Jun 2025
Q1 2025 10% +1.1% +12% 31 Mar 2025
Q4 2024 9.4% -1.4% -13% 31 Dec 2024
Q3 2024 9.3% -1.2% -12% 30 Sep 2024
Q2 2024 9.4% -1% -10% 30 Jun 2024
Q1 2024 9.4% -1.4% -13% 31 Mar 2024
Q4 2023 11% +0.77% +7.7% 31 Dec 2023
Q3 2023 10% +0.9% +9.4% 30 Sep 2023
Q2 2023 10% +1.6% +18% 30 Jun 2023
Q1 2023 11% +3.3% +45% 31 Mar 2023
Q4 2022 10% +4% +66% 31 Dec 2022
Q3 2022 9.6% +5.1% +115% 30 Sep 2022
Q2 2022 8.8% +5.4% +160% 30 Jun 2022
Q1 2022 7.4% +4.2% +130% 31 Mar 2022
Q4 2021 6% +1.1% +22% 31 Dec 2021
Q3 2021 4.4% -8.7% -66% 30 Sep 2021
Q2 2021 3.4% 30 Jun 2021
Q1 2021 3.2% 31 Mar 2021
Q4 2020 4.9% 31 Dec 2020
Q3 2020 13% 30 Sep 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.